The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence
of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a …

Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with
or without in-transit metastases, represents approximately 15% of new melanoma diagnoses …

Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment approach for
patients with surgically resectable macroscopic stage III melanoma. The neoadjuvant setting …

Background Phase 1–2 trials involving patients with resectable, macroscopic stage III
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …

Opinion statement Patients with clinical stage III melanoma, defined as palpable lymph
nodes with or without in-transit metastases, have poor prognosis even with recent advances …

Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint
blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently …

Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …

9503 Background: Pathological complete response (pCR) to neoadjuvant systemic therapy
(NST) correlates with survival, and is recognized as a path to regulatory approval in several …

The treatment of malignant melanoma has drastically changed over the past decade with the
advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and …

The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …